February 20, 2026

BioMed X Advances Women’s Health Innovation at Inaugural XFem Labs Pitch & Connect Event – Joint Event with bioRN

BioMed X Advances Women’s Health Innovation at Inaugural XFem Labs Pitch & Connect Event – Joint Event with bioRN
  • The event marked the launch of BioMed X’s new Women’s Health R&D Accelerator, supported by the Gates Foundation, and featured final pitch presentations on “New Strategies for Female-Controlled Non-Hormonal Contraception.”

You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information


Heidelberg, Germany, 17 February 2026 ­- 
BioMed X, a leading innovation hub for pharma headquartered in Heidelberg, hosted the first XFem Labs Pitch & Connect event on February 13th in Heidelberg, marking the official launch of XFem Labs, its new Women’s Health R&D Accelerator established with support from the Gates Foundation. The purpose of this initiative is to build a world-class women’s health innovation hub in Heidelberg that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries.

The Pitch & Connect event showcased the final presentations of the first five teams focusing on “New Strategies for Female-Controlled Non-Hormonal Contraception”. The winning team will use the $2 million grant made available to BioMed X by the Gates Foundation to advance their proposal. In the coming months, the researchers will be relocated to the vibrant biomedical research ecosystem in Heidelberg and develop a proof-of-concept for a new generation of contraceptives.

Despite the availability of various contraceptive methods, significant unmet needs remain for non-hormonal, female-controlled alternatives. The diverse approaches presented at the Pitch & Connect event reflected this urgency and underscored the potential for novel biological targets, mechanisms, and delivery modalities that extend beyond current options, with a particular focus on solutions that are scalable, affordable, and feasible for use in low- and middle-income countries.

The event attracted a select community of investors, sponsors, strategic partners, and thought leaders committed to advancing innovation in women’s health R&D. Participants engaged in discussions on the future of women’s health and opportunities for collaboration and co-investment.

“It is so good to see that there’s a whole initiative about the women’s health that is taking the industry, basic research and startup together to work on this important cause. I really appreciate BioMed X and the Gates Foundation for taking this initiative.”
Amrita Jain, Investment Director, DeepbrightVC

“Today is a very important event to address not only Women’s Health issues but going even beyond that. Considering the teams have met 4 days ago and had about 3 days to come up with the whole concept, it was very fascinating to see such well scientifically developed and thought through concepts.”
Markus Dietrich, Senior Investment Associate, Hadean Ventures

“Today has been truly inspiring. Women-controlled, non-hormonal contraception offers meaningful choice, autonomy, and empowerment, addressing a critical unmet need in health, particularly in Sub-Saharan Africa. I am encouraged to see BioMed X and other partners investing in this space, and I am hopeful that the discussions today will help advance at least one of the promising concepts presented toward implementation.”
Nyaradzo Mgodi, University of Zimbabwe Faculty of Medicine and Health Sciences

“It’s great to be here today and hear all the exiting pitches from these young researchers. This creates a great opportunity for Heidelberg to become a leading scientific hub in Europe for Women’s Health”.
Pabla van Heck, Insight Researcher & Creative Strategist for Inclusive Innovation/ Business & Human Rights/ Social Innovation

This event was a joint initiative of BioMed X and the bioRN Life Science Cluster, based in Heidelberg, one of the most vibrant life science ecosystem in Europe with more than 180 members.

About XFem Labs
XFem Labs is a Women’s Health R&D Accelerator based in Heidelberg, Germany, supported by the Gates Foundation. Its purpose is to establish a world-class women’s health innovation hub that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries.

About BioMed X

BioMed X is a leading innovation hub for pharma. With our global network of research institutes at top universities and incubators within pharmaceutical companies, we bridge the gap between academia and industry. We are pioneers in applying the principles of design thinking and crowdsourcing to drug discovery and development. With our unique model, we identify key challenges across all therapeutic areas, recruit top academic talent, and co-create tailored solutions with our pharma partners. In our stimulating ecosystem, early-career researchers grow into future scientific leaders. They perform exploratory research, deliver industry-grade results, and pave the way to next-generation therapies. At BioMed X, we value curiosity, diversity, and purpose. Our goal is to serve as a vital catalyst for innovation in global health for the benefit of all patients.

Our latest News

discover more
SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings

SPT Labtech to collaborate with Illumina to develop automated platform supporting genomics in decentralized healthcare settings

Cambridge, UK, 25 February 2026: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, today announced a strategic collaboration with Illumina to develop a novel automated sample preparation platform designed to streamline and standardize genomics workflows across decentralized healthcare environments. The collaboration will focus on helping labs […]

€1.48 Million in Federal Funding Secured for SAM3 Research Project at Mannheim University of Applied Sciences

€1.48 Million in Federal Funding Secured for SAM3 Research Project at Mannheim University of Applied Sciences

Mannheim University of Applied Sciences has been awarded approximately €1.48 million in federal funding for the research project SAM3 – Smart Applications for Multimodal Molecular Pattern Recognition (2026–2028). The funding is provided through the “HAW-ForschungsPraxis 2024” program of the German Federal Ministry for Research, Technology and Space. The project focuses on advancing biochemical analytics used […]

Seeing cells in a new light

Seeing cells in a new light

Illuminating the tiniest details of living cells just got a major boost: Scientists at the Max Planck Institute for Medical Research have developed new markers that glow in the far-red range and are activated by light. They are stable, easy to control, and compatible with several super-resolution microscopy techniques, as outlined in a paper published […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp